%0 Journal Article
%T Boron delivery agents for neutron capture therapy of cancer
%A Peng Mi
%A Rolf F. Barth
%A Weilian Yang
%J Archive of "Cancer Communications".
%D 2018
%R 10.1186/s40880-018-0299-7
%X Boron neutron capture therapy is based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, a constituent of natural elemental boron, 80% of which is in the isotopic form of 11B and 20% as 10B, is irradiated with low-energy (0.025 eV) thermal neutrons or, alternatively, higher-energy (10,000 eV) epithermal neutrons. The latter become thermalized as they penetrate tissues. The resulting 10B(n,¦Á)7Li capture reaction yiels high linear energy transfer (LET) ¦Á paricles (stripped down helium nuclei [4He]) and recoiling lithium-7 (7Li) atoms (a). A sufficient amount of 10B must be delivered selectively to the tumor (~£¿20¨C50 ¦Ìg/g or ~£¿109 atoms/cell) in order for BNCT to be successful (b). A collimated beam of either thermal or epithermal neutrons must be absorbed by the tumor cells to sustain a lethal 10B(n,¦Á)7Li capture reaction. Since the ¦Á paricles have very short pathlengths in tissues (5¨C9 ¦Ìm), their destructive effects are limite to boron-containing cells. In theory, BNCT provides a way to selectively destroy malignant cells and spare surrounding normal tissue if the required amounts of 10B and neutrons are delivered to the tumor cells
%K Boron delivery agents
%K Neutron capture therapy
%K Brain tumors
%K Head and neck cancer
%K Melanoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006782/